Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 10/20 | 0.46 |
| ▸ | XIAP | P98170 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | PTGER4 | P35408 | 3/20 | 0.35 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | DPP4 | P27487 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19661451 | 1.00 | CTSK (0.46) | CTSKXIAPCYP3A4CYP2D6PTGER4 | |
| SCHEMBL18426529 | 0.87 | XIAP (0.41) | CTSKXIAPDPP4 | |
| SCHEMBL13108121 | 0.85 | XIAP (0.40) | CTSKXIAPCYP3A4CYP2D6 | |
| SCHEMBL20276028 | 0.83 | CTSK (0.40) | CTSKXIAPCYP3A4CYP2D6PTGER4 | |
| SCHEMBL18541518 | 0.83 | CTSK (0.40) | CTSKXIAPCYP3A4CYP2D6PTGER4 | |
| SCHEMBL16002512 | 0.82 | CTSK (0.39) | CTSKXIAPCYP3A4CYP2D6PTGER4 | |
| SCHEMBL19648669 | 0.82 | CTSK (0.39) | CTSKXIAPCYP3A4CYP2D6PTGER4 | |
| SCHEMBL15739324 | 0.81 | XIAP (0.44) | CTSKXIAPCYP3A4CYP2D6PTGER4 | |
| SCHEMBL16143195 | 0.81 | XIAP (0.44) | CTSKXIAPCYP3A4CYP2D6PTGER4 | |
| SCHEMBL19648496 | 0.81 | XIAP (0.44) | CTSKXIAPCYP3A4CYP2D6PTGER4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3838298-A2 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | Purdue Research Foundation (US) | 2021-06-23 | — | — | EP | disclosed |
| EP-3831380-A2 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | Purdue Research Foundation (US) | 2021-06-09 | — | — | EP | disclosed |
| US-10010618-B2 | Methods for treating cancer using combination therapies | ENDOCYTE, INC. (US) | 2018-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10010618-B2 | Methods for treating cancer using combination therapies | SLC7A11, CXCR2, TPX2 | CTSK 535/4885XIAP 41/4885CYP3A4 3409/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.